Mommox (Mometasone Furoate)

Mometasone furoate is a glucocorticoid receptor agonist. By binding to intracellular glucocorticoid receptors in nasal mucosal cells, it modulates gene transcription, decreasing production of inflammatory cytokines, chemokines and prostaglandins, thereby suppressing the local immune response and reducing swelling and mucus.

The specific dose of Mommox is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Typical regimens involve one or two sprays per nostril once daily, but exact instructions must be obtained from the prescriber.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. It is classified as pregnancy category unknown, and clinicians usually weigh potential benefits against risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mommox. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mommox (mometasone furoate) is a high‑potency intranasal corticosteroid with low systemic bioavailability, similar to fluticasone propionate and budesonide. Compared with lower‑potency agents, it may achieve symptom control with fewer sprays, but choice depends on individual response, tolerability and physician preference.

Store Mommox at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture, heat and direct sunlight. Do not freeze the product, and keep it out of reach of children.

Mommox is administered as a nasal spray. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator while breathing in gently through the nose. The recommended number of sprays per nostril is provided by the prescriber.

Although rare, serious adverse events can include nasal septal perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Patients should seek immediate medical attention if they experience unusual bleeding, severe pain, or signs of systemic corticosteroid effects.

Mommox should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery, or those who have experienced severe local reactions to intranasal corticosteroids. Consultation with a healthcare professional is essential before initiating therapy.